权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Study on plasma HDL-C concentration and HDL remodeling in CETP genc polymorphism

CETP基因多态性血浆HDL-C浓度及HDL重构研究

基本信息

批准号：
12671129
负责人：
MURAKAMI Toru
金额：
$ 0.7万
依托单位：
Tokushima Bunri University
依托单位国家：
日本
项目类别：
Grant-in-Aid for Scientific Research (C)
财政年份：
2000
资助国家：
日本
起止时间：
2000 至 2001
项目状态：
已结题

来源：
https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-12671129/
关键词：
HDL CETP Taq IB polymorphism HL-514 C T polymorphism Reverse cholesterol transport Atheroselerosis Diabetes Mellitus Statin HDL-C 動脈硬化惹起性 HDLリモデリング高脂血症

项目摘要

CETP Taq I B B1B1 polymorphism was an important genotype affecting to plasma HDL cholesterol concentration in multiple clinical factors matched subjects. It was shown that the level of plasma HDL-C of the subjects with B1B1 polymorphism was lower about 8% compared with those of B2B2.In diabetic patients, the level of plasma HDL-C of the subjects with B2B2 was higher about 20% compared with those of B1B1.However it was indicated that this result had not always good effects to prevent atherosclerosis. Because in diabetic patients, the ability of cholesterol transport from donor lipoprotein to acceptor lipoproteins is basically decreased. Therefore increased plasma HDL-C level by the inhibitory effect of reverse cholesterol transport will not be contributed to the prevention of atherosclerosis. Our study furthermore indicated that this condition was more enhanced in patients with hypertriglyceridemics and obesity. We concluded that Taq IB B2B2 genotype itself may contribute to the increment of plasma HDL-C concentration but the role of this gene polymorphism concerning the preventive effects for atherosclerosis in diabetics, obese subjects and hypertriglyceridemics was controversial. Recently we found that the effect of HDL-C increment after statin was the strongest in primary hypercholesterolemics with CETP Taq IB B1B1 polymorphism.

在多个临床因素匹配的人群中，CETP Taq I B B1基因多态性是影响血浆HDL胆固醇浓度的重要基因型。结果表明，B1 B1基因多态性者的血浆HDL-C水平比B2 B2基因多态性者低8%左右，而在糖尿病患者中，B2 B2基因多态性者的血浆HDL-C水平比B1 B1基因多态性者高20%左右。因为在糖尿病患者中，胆固醇从供体脂蛋白转运到受体脂蛋白的能力基本上是下降的。因此，通过胆固醇逆向转运的抑制作用而升高血浆HDL-C水平将无助于预防动脉粥样硬化。我们的研究进一步表明，这种情况在高血压和肥胖患者中更明显。我们的结论是，Taq IB B2 B2基因型本身可能有助于血浆HDL-C浓度的增加，但该基因多态性在糖尿病、肥胖和高血压患者中预防动脉粥样硬化的作用是有争议的。最近我们发现，在CETP Taq IB B1 B1多态性的原发性高胆固醇血症患者中，他汀类药物治疗后HDL-C升高的效果最强。